| Latrena Montgomery, FNP-C | |
|
105 Varese Pl, Madison, MS 39110 | |
| (601) 622-8182 | |
| Not Available |
| Full Name | Latrena Montgomery |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 11 Years |
| Location | 105 Varese Pl, Madison, Mississippi |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1346621075 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | R881572 (Mississippi) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| State Of Mississippi - University Of Mississippi Medical Center | 1850293036 | 804 |
News Archive
World Heart Corporation, a developer of mechanical circulatory systems, announced today that the Massachusetts General Hospital in Boston, Mass. has successfully implanted its first Levacor™ Ventricular Assist Device (VAD). Mass General is the fifth implanting site nationwide in the Levacor VAD Bridge-to-Transplant (BTT) Study. This is the eleventh implant with the Levacor VAD since the inception of the BTT study.
Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company was awarded a Qualifying Therapeutic Discovery Project (QTDP) credit from the Federal Government for ADXS11-001, the Company's lead immunotherapeutic construct totaling $244,479.
A global team of researchers, led by a research team at the Liverpool School of Tropical Medicine (LSTM), are calling for a review of drug-based strategies used to prevent malaria infections in pregnant women, in areas where there is widespread resistance to existing antimalarial medicines.
How women make decisions about treatment while suffering a miscarriage, and the key factors that influence their choices, are revealed in a study published in Obstetrics & Gynecology from researchers at the Perelman School of Medicine at the University of Pennsylvania.
Patients who acquire skin and soft tissue infections (SSTIs) in a hospital or other healthcare setting may be more likely to receive inappropriate antibiotic therapy at the beginning of their treatment. As a result, they also may have significantly longer hospital stays to control the infection.
› Verified 7 days ago
| Entity Name | G A Carmichael Family Health Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801952809 PECOS PAC ID: 2567371032 Enrollment ID: O20050816001055 |
News Archive
World Heart Corporation, a developer of mechanical circulatory systems, announced today that the Massachusetts General Hospital in Boston, Mass. has successfully implanted its first Levacor™ Ventricular Assist Device (VAD). Mass General is the fifth implanting site nationwide in the Levacor VAD Bridge-to-Transplant (BTT) Study. This is the eleventh implant with the Levacor VAD since the inception of the BTT study.
Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company was awarded a Qualifying Therapeutic Discovery Project (QTDP) credit from the Federal Government for ADXS11-001, the Company's lead immunotherapeutic construct totaling $244,479.
A global team of researchers, led by a research team at the Liverpool School of Tropical Medicine (LSTM), are calling for a review of drug-based strategies used to prevent malaria infections in pregnant women, in areas where there is widespread resistance to existing antimalarial medicines.
How women make decisions about treatment while suffering a miscarriage, and the key factors that influence their choices, are revealed in a study published in Obstetrics & Gynecology from researchers at the Perelman School of Medicine at the University of Pennsylvania.
Patients who acquire skin and soft tissue infections (SSTIs) in a hospital or other healthcare setting may be more likely to receive inappropriate antibiotic therapy at the beginning of their treatment. As a result, they also may have significantly longer hospital stays to control the infection.
› Verified 7 days ago
| Entity Name | State Of Mississippi - University Of Mississippi Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154317527 PECOS PAC ID: 1850293036 Enrollment ID: O20090414000575 |
News Archive
World Heart Corporation, a developer of mechanical circulatory systems, announced today that the Massachusetts General Hospital in Boston, Mass. has successfully implanted its first Levacor™ Ventricular Assist Device (VAD). Mass General is the fifth implanting site nationwide in the Levacor VAD Bridge-to-Transplant (BTT) Study. This is the eleventh implant with the Levacor VAD since the inception of the BTT study.
Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company was awarded a Qualifying Therapeutic Discovery Project (QTDP) credit from the Federal Government for ADXS11-001, the Company's lead immunotherapeutic construct totaling $244,479.
A global team of researchers, led by a research team at the Liverpool School of Tropical Medicine (LSTM), are calling for a review of drug-based strategies used to prevent malaria infections in pregnant women, in areas where there is widespread resistance to existing antimalarial medicines.
How women make decisions about treatment while suffering a miscarriage, and the key factors that influence their choices, are revealed in a study published in Obstetrics & Gynecology from researchers at the Perelman School of Medicine at the University of Pennsylvania.
Patients who acquire skin and soft tissue infections (SSTIs) in a hospital or other healthcare setting may be more likely to receive inappropriate antibiotic therapy at the beginning of their treatment. As a result, they also may have significantly longer hospital stays to control the infection.
› Verified 7 days ago
| Entity Name | Mississippi Emergency Physician Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710220678 PECOS PAC ID: 2264672492 Enrollment ID: O20130710000827 |
News Archive
World Heart Corporation, a developer of mechanical circulatory systems, announced today that the Massachusetts General Hospital in Boston, Mass. has successfully implanted its first Levacor™ Ventricular Assist Device (VAD). Mass General is the fifth implanting site nationwide in the Levacor VAD Bridge-to-Transplant (BTT) Study. This is the eleventh implant with the Levacor VAD since the inception of the BTT study.
Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company was awarded a Qualifying Therapeutic Discovery Project (QTDP) credit from the Federal Government for ADXS11-001, the Company's lead immunotherapeutic construct totaling $244,479.
A global team of researchers, led by a research team at the Liverpool School of Tropical Medicine (LSTM), are calling for a review of drug-based strategies used to prevent malaria infections in pregnant women, in areas where there is widespread resistance to existing antimalarial medicines.
How women make decisions about treatment while suffering a miscarriage, and the key factors that influence their choices, are revealed in a study published in Obstetrics & Gynecology from researchers at the Perelman School of Medicine at the University of Pennsylvania.
Patients who acquire skin and soft tissue infections (SSTIs) in a hospital or other healthcare setting may be more likely to receive inappropriate antibiotic therapy at the beginning of their treatment. As a result, they also may have significantly longer hospital stays to control the infection.
› Verified 7 days ago
| Entity Name | Capital Emergency Physicians Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528405230 PECOS PAC ID: 0244471480 Enrollment ID: O20130730000783 |
News Archive
World Heart Corporation, a developer of mechanical circulatory systems, announced today that the Massachusetts General Hospital in Boston, Mass. has successfully implanted its first Levacor™ Ventricular Assist Device (VAD). Mass General is the fifth implanting site nationwide in the Levacor VAD Bridge-to-Transplant (BTT) Study. This is the eleventh implant with the Levacor VAD since the inception of the BTT study.
Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company was awarded a Qualifying Therapeutic Discovery Project (QTDP) credit from the Federal Government for ADXS11-001, the Company's lead immunotherapeutic construct totaling $244,479.
A global team of researchers, led by a research team at the Liverpool School of Tropical Medicine (LSTM), are calling for a review of drug-based strategies used to prevent malaria infections in pregnant women, in areas where there is widespread resistance to existing antimalarial medicines.
How women make decisions about treatment while suffering a miscarriage, and the key factors that influence their choices, are revealed in a study published in Obstetrics & Gynecology from researchers at the Perelman School of Medicine at the University of Pennsylvania.
Patients who acquire skin and soft tissue infections (SSTIs) in a hospital or other healthcare setting may be more likely to receive inappropriate antibiotic therapy at the beginning of their treatment. As a result, they also may have significantly longer hospital stays to control the infection.
› Verified 7 days ago
| Entity Name | Capital Emergency Physicians Madison Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194176644 PECOS PAC ID: 6406140631 Enrollment ID: O20160810001113 |
News Archive
World Heart Corporation, a developer of mechanical circulatory systems, announced today that the Massachusetts General Hospital in Boston, Mass. has successfully implanted its first Levacor™ Ventricular Assist Device (VAD). Mass General is the fifth implanting site nationwide in the Levacor VAD Bridge-to-Transplant (BTT) Study. This is the eleventh implant with the Levacor VAD since the inception of the BTT study.
Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company was awarded a Qualifying Therapeutic Discovery Project (QTDP) credit from the Federal Government for ADXS11-001, the Company's lead immunotherapeutic construct totaling $244,479.
A global team of researchers, led by a research team at the Liverpool School of Tropical Medicine (LSTM), are calling for a review of drug-based strategies used to prevent malaria infections in pregnant women, in areas where there is widespread resistance to existing antimalarial medicines.
How women make decisions about treatment while suffering a miscarriage, and the key factors that influence their choices, are revealed in a study published in Obstetrics & Gynecology from researchers at the Perelman School of Medicine at the University of Pennsylvania.
Patients who acquire skin and soft tissue infections (SSTIs) in a hospital or other healthcare setting may be more likely to receive inappropriate antibiotic therapy at the beginning of their treatment. As a result, they also may have significantly longer hospital stays to control the infection.
› Verified 7 days ago
| Entity Name | App Of Mississippi Ed Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730687740 PECOS PAC ID: 3971865858 Enrollment ID: O20180313002534 |
News Archive
World Heart Corporation, a developer of mechanical circulatory systems, announced today that the Massachusetts General Hospital in Boston, Mass. has successfully implanted its first Levacor™ Ventricular Assist Device (VAD). Mass General is the fifth implanting site nationwide in the Levacor VAD Bridge-to-Transplant (BTT) Study. This is the eleventh implant with the Levacor VAD since the inception of the BTT study.
Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company was awarded a Qualifying Therapeutic Discovery Project (QTDP) credit from the Federal Government for ADXS11-001, the Company's lead immunotherapeutic construct totaling $244,479.
A global team of researchers, led by a research team at the Liverpool School of Tropical Medicine (LSTM), are calling for a review of drug-based strategies used to prevent malaria infections in pregnant women, in areas where there is widespread resistance to existing antimalarial medicines.
How women make decisions about treatment while suffering a miscarriage, and the key factors that influence their choices, are revealed in a study published in Obstetrics & Gynecology from researchers at the Perelman School of Medicine at the University of Pennsylvania.
Patients who acquire skin and soft tissue infections (SSTIs) in a hospital or other healthcare setting may be more likely to receive inappropriate antibiotic therapy at the beginning of their treatment. As a result, they also may have significantly longer hospital stays to control the infection.
› Verified 7 days ago
| Entity Name | Yazoo Emergency Group, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447806914 PECOS PAC ID: 0749511574 Enrollment ID: O20191009002380 |
News Archive
World Heart Corporation, a developer of mechanical circulatory systems, announced today that the Massachusetts General Hospital in Boston, Mass. has successfully implanted its first Levacor™ Ventricular Assist Device (VAD). Mass General is the fifth implanting site nationwide in the Levacor VAD Bridge-to-Transplant (BTT) Study. This is the eleventh implant with the Levacor VAD since the inception of the BTT study.
Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company was awarded a Qualifying Therapeutic Discovery Project (QTDP) credit from the Federal Government for ADXS11-001, the Company's lead immunotherapeutic construct totaling $244,479.
A global team of researchers, led by a research team at the Liverpool School of Tropical Medicine (LSTM), are calling for a review of drug-based strategies used to prevent malaria infections in pregnant women, in areas where there is widespread resistance to existing antimalarial medicines.
How women make decisions about treatment while suffering a miscarriage, and the key factors that influence their choices, are revealed in a study published in Obstetrics & Gynecology from researchers at the Perelman School of Medicine at the University of Pennsylvania.
Patients who acquire skin and soft tissue infections (SSTIs) in a hospital or other healthcare setting may be more likely to receive inappropriate antibiotic therapy at the beginning of their treatment. As a result, they also may have significantly longer hospital stays to control the infection.
› Verified 7 days ago
| Entity Name | Jackson Hb Medical Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184305856 PECOS PAC ID: 6103273131 Enrollment ID: O20231113001051 |
News Archive
World Heart Corporation, a developer of mechanical circulatory systems, announced today that the Massachusetts General Hospital in Boston, Mass. has successfully implanted its first Levacor™ Ventricular Assist Device (VAD). Mass General is the fifth implanting site nationwide in the Levacor VAD Bridge-to-Transplant (BTT) Study. This is the eleventh implant with the Levacor VAD since the inception of the BTT study.
Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company was awarded a Qualifying Therapeutic Discovery Project (QTDP) credit from the Federal Government for ADXS11-001, the Company's lead immunotherapeutic construct totaling $244,479.
A global team of researchers, led by a research team at the Liverpool School of Tropical Medicine (LSTM), are calling for a review of drug-based strategies used to prevent malaria infections in pregnant women, in areas where there is widespread resistance to existing antimalarial medicines.
How women make decisions about treatment while suffering a miscarriage, and the key factors that influence their choices, are revealed in a study published in Obstetrics & Gynecology from researchers at the Perelman School of Medicine at the University of Pennsylvania.
Patients who acquire skin and soft tissue infections (SSTIs) in a hospital or other healthcare setting may be more likely to receive inappropriate antibiotic therapy at the beginning of their treatment. As a result, they also may have significantly longer hospital stays to control the infection.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Latrena Montgomery, FNP-C 1668 W Peace St, Canton, MS 39046-5332 Ph: (601) 622-8182 | Latrena Montgomery, FNP-C 105 Varese Pl, Madison, MS 39110 Ph: (601) 622-8182 |
News Archive
World Heart Corporation, a developer of mechanical circulatory systems, announced today that the Massachusetts General Hospital in Boston, Mass. has successfully implanted its first Levacor™ Ventricular Assist Device (VAD). Mass General is the fifth implanting site nationwide in the Levacor VAD Bridge-to-Transplant (BTT) Study. This is the eleventh implant with the Levacor VAD since the inception of the BTT study.
Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company was awarded a Qualifying Therapeutic Discovery Project (QTDP) credit from the Federal Government for ADXS11-001, the Company's lead immunotherapeutic construct totaling $244,479.
A global team of researchers, led by a research team at the Liverpool School of Tropical Medicine (LSTM), are calling for a review of drug-based strategies used to prevent malaria infections in pregnant women, in areas where there is widespread resistance to existing antimalarial medicines.
How women make decisions about treatment while suffering a miscarriage, and the key factors that influence their choices, are revealed in a study published in Obstetrics & Gynecology from researchers at the Perelman School of Medicine at the University of Pennsylvania.
Patients who acquire skin and soft tissue infections (SSTIs) in a hospital or other healthcare setting may be more likely to receive inappropriate antibiotic therapy at the beginning of their treatment. As a result, they also may have significantly longer hospital stays to control the infection.
› Verified 7 days ago
Mallory Elizabeth Boggs, A-GNP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 159 Fountains Blvd Ste B, Madison, MS 39110 Phone: 601-859-8200 | |
Mary Hamilton Harkins, MSN, NP-C Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1082 Gluckstadt Rd, Madison, MS 39110 Phone: 601-707-5621 | |
Ms. Larona Rachelle Searcy, FNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 161 Woodland Dr, Madison, MS 39110 Phone: 601-503-0335 | |
Allison Ayers Cochran, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 102 Lexington Dr Ste 100, Madison, MS 39110 Phone: 601-973-1688 Fax: 601-973-1690 | |
Heather Hontzas, Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 159 Fountains Blvd Ste A, Madison, MS 39110 Phone: 769-231-1400 | |
Dean E Whitley, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 794 Highway 51, Suite D, Madison, MS 39110 Phone: 601-853-8814 Fax: 601-853-8816 | |
Mrs. Rebecca L Cauthen, ACNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 189 Saddlebrook Cv, Madison, MS 39110 Phone: 601-818-0020 |